Botulism cost-effectiveness of therapy

Botulism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Botulism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Botulism cost-effectiveness of therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Botulism cost-effectiveness of therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Botulism cost-effectiveness of therapy
CDC on Botulism cost-effectiveness of therapy
Botulism cost-effectiveness of therapy in the news
Blogs on Botulism cost-effectiveness of therapy
Directions to Hospitals Treating Botulism
Risk calculators and risk factors for Botulism cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Michael Maddaleni, B.S., Hafiz M. Ahmed, M.D.[2]

Overview

The CDC 2021 guideline does not provide a formal cost-effectiveness evaluation of botulism treatments. It describes improved clinical outcomes and reduced hospital resource use associated with early antitoxin treatment, but these findings should not be interpreted as a formal economic comparison of treatment strategies.

References

Template:WikiDoc Sources